EyePoint Pharmaceuticals Inc.

About

EyePoint is a biopharmaceutical company dedicated to developing innovative therapeutics aimed at improving the lives of patients suffering from serious retinal diseases. The company focuses on creating sustained-release medications to treat ocular disorders, leveraging advanced drug delivery technologies. With a commitment to patient care, EyePoint's leadership team comprises experienced professionals from various fields, including ophthalmology, finance, and regulatory affairs, all working towards enhancing treatment options for retinal conditions.

Verified company data

Cash position

$118 million

Projects

["DURAVYU™ vorolanib intravitreal insert (tyrosine kinase inhibitor) (a/k/a EYP-1901): Wet AMD - Discovery, Pre-Clinical, Phase 1, Phase 2, Phase 3. Trial Underway. LUGANO Topline Data Reported; LUCIA Fully Enrolled. Wet AMD Clinical Trial Progress | LUCIA topline data expected in 4Q 2026.","DURAVYU™ vorolanib intravitreal insert (tyrosine kinase inhibitor) (a/k/a EYP-1901): DME - Discovery, Pre-Clinical, Phase 1, Phase 2, Phase 3. Trial Underway. COMO and CAPRI Fully Enrolled. DME Clinical Trial Progress | COMO and CAPRI topline data expected in Q4 2027.","DURAVYU™ vorolanib intravitreal insert (tyrosine kinase inhibitor) (a/k/a EYP-1901): Undisclosed candidates - Retinal Diseases - Discovery, Pre-Clinical, Phase 1, Phase 2, Phase 3. Trial Underway. Non-Clinical. Retinal Diseases Clinical Trial Progress.","Lugano: A phase 3 study evaluating the efficacy and safety of DURAVYU™ in subjects with wAMD. Active.","Lucia: A phase 3 study evaluating the efficacy and safety of DURAVYU™ in subjects with wAMD. Active.","DAVIO 2: A phase 2 study evaluating the efficacy and safety of DURAVYU™ in subjects with wAMD. Completed.","Verona: A phase 3 study evaluating the efficacy and safety of DURAVYU™ in subjects with DME. Active.","CAPRI: A phase 3 study evaluating the efficacy and safety of DURAVYU™ in subjects with DME. Active.","Verona: A phase 2 study evaluating the efficacy and safety of DURAVYU™ in subjects with DME. Completed."]

Leadership

Tarek S. Hassan, M.D. (Chief Strategic Science Officer, Appointed to lead strategic scientific initiatives at EyePoint.)

Verified data last updated: 2026-10-30

Recent filings

• [Amend] Statement of acquisition of beneficial ownership by individuals2026-11-04 · eypt_2026-11-04_12-51-55.pdf→
• [Amend] Statement of acquisition of beneficial ownership by individuals2026-10-30 · eypt_2026-10-30_14-45-07.pdf→
• Statement of acquisition of beneficial ownership by individuals2026-10-27 · eypt_2026-10-27_20-51-40.pdf→
• Current report pursuant to Section 13 or 15(d)2026-10-19 · eypt_2026-10-19_10-05-19.pdf→
• [Amend] Statement of acquisition of beneficial ownership by individuals2026-10-07 · eypt_2026-10-07_10-22-39.pdf→
• Current report pursuant to Section 13 or 15(d)2026-09-10 · eypt_2026-09-10_10-05-24.pdf→
• Statement of acquisition of beneficial ownership by individuals2026-09-08 · eypt_2026-09-08_14-50-53.pdf→
• Statement of changes in beneficial ownership of securities2026-08-24 · eypt_2026-08-24_19-10-53.pdf→